Lerchbaumer MH, Ebner M, Ritter CO, Steimke L, Rogge NIJ, Sentler C, Thielmann A, Hobohm L, Keller K, Lotz J, Hasenfuß G, Wachter R, Hamm B, Konstantinides SV, Aviram G, and Lankeit M
Aims: Right atrial (RA) dilation and stretch provide prognostic information in patients with cardiovascular diseases. We investigated the prevalence, confounding factors and prognostic relevance of RA dilation in patients with pulmonary embolism (PE)., Methods: Overall, 609 PE patients were consecutively included in a prospective single-centre registry between September 2008 and August 2017. Volumetric measurements of heart chambers were performed on routine non-electrocardiographic-gated computed tomography and plasma concentrations of mid-regional pro-atrial natriuretic peptide (MR-proANP) measured on admission. An in-hospital adverse outcome was defined as PE-related death, cardiopulmonary resuscitation, mechanical ventilation or catecholamine administration., Results: Patients with an adverse outcome (11.2%) had larger RA volumes (median 120 (interquartile range 84-152) versus 102 (78-134) mL; p=0.013), RA/left atrial (LA) volume ratios (1.7 (1.2-2.4) versus 1.3 (1.1-1.7); p<0.001) and MR-proANP levels (282 (157-481) versus 129 (64-238) pmol·L -1 ; p<0.001) compared to patients with a favourable outcome. Overall, 499 patients (81.9%) had a RA/LA volume ratio ≥1.0 and a calculated cut-off value of 1.8 (area under the curve 0.64, 95% CI 0.56-0.71) predicted an adverse outcome, both in unselected (OR 3.1, 95% CI 1.9-5.2) and normotensive patients (OR 2.7, 95% CI 1.3-5.6). MR-proANP ≥120 pmol·L -1 was identified as an independent predictor of an adverse outcome, both in unselected (OR 4.6, 95% CI 2.3-9.3) and normotensive patients (OR 5.1, 95% CI 1.5-17.6)., Conclusions: RA dilation is a frequent finding in patients with PE. However, the prognostic performance of RA dilation appears inferior compared to established risk stratification markers. MR-proANP predicted an in-hospital adverse outcome, both in unselected and normotensive PE patients, integrating different prognostic relevant information from comorbidities., Competing Interests: Conflict of interest: M.H. Lerchbaumer reports having received consultancy honoraria from Siemens Healthineers. Conflict of interest: M. Ebner has nothing to disclose. Conflict of interest: C.O. Ritter has nothing to disclose. Conflict of interest: L. Steimke has nothing to disclose. Conflict of interest: N.I.J. Rogge has nothing to disclose. Conflict of interest: C. Sentler has nothing to disclose. Conflict of interest: A. Thielmann has nothing to disclose. Conflict of interest: L. Hobohm reports personal fees from MSD and Actelion outside the submitted work. Conflict of interest: K. Keller has nothing to disclose. Conflict of interest: J. Lotz has nothing to disclose. Conflict of interest: G. Hasenfuß reports personal fees from Corvia, Servier, Impulse Dynamics, Novartis, AstraZeneca, Vifor Pharma, Berlin Chemie and Springer outside the submitted work. Conflict of interest: R. Wachter reports grants from Boehringer Ingelheim during the conduct of the study; personal fees and other support from Bayer, Berlin Chemie and Boehringer Ingelheim, other support from Boston Scientific, personal fees from Bristol-Myers-Squibb, personal fees and other support from CVRx, other support from Gilead and Johnson & Johnson, personal fees and other support from Medtronic and Novartis, personal fees from Pfizer, other support from Relypsa, personal fees from Sanofi, and personal fees and other support from Servier, outside the submitted work. Conflict of interest: B. Hamm reports personal fees from Canon Medical Imaging outside the submitted work. Conflict of interest: S.V. Konstantinides reports grants from the German Federal Ministry of Education and Research (BMBF 01EO1003 and BMBF 01EO1503) during the conduct of the study; grants and personal fees from Bayer, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Daiichi-Sankyo, personal fees from MSD, grants and personal fees from Pfizer–Bristol-Myers-Squibb, and grants and personal fees from Actelion, outside the submitted work. Conflict of interest: G. Aviram reports grants from Philips Medical Systems outside the submitted work. Conflict of interest: M. Lankeit reports grants from the German Federal Ministry of Education and Research (BMBF 01EO1003 and 01EO1503), and BRAHMS–Thermo Fisher Scientific, during the conduct of the study; and personal fees and nonfinancial support from Actelion, Bayer, Daiichi-Sankyo, MSD and Pfizer–Bristol-Myers-Squibb, and grants and personal fees from BRAHMS–Thermo Fisher Scientific, outside the submitted work., (Copyright ©ERS 2021.)